Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beclomethasone dipropionate via breath-actuated or metered-dose inhaler in children with persistent asthma
2013-004632-30Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of beclomethasone dipropionate in persistent asthma (5 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Standardized baseline-adjusted trough morning percent predicted FEV1 AUEC 0-12 weeks. Started Apr 2015; status: completed.
02
Drugs
beclomethasone dipropionate
03
Conditions
persistent asthma
Beyond the preview
Go deeper on 2013-004632-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004632-30.